Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,361 to 1,380 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nanodrugs Targeting T Cells in Tumor Therapy. | Front Immunol | 2022 | 35693776 | PubTator, text mining | PubMed |
| Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling. | Front Genet | 2022 | 35692836 | PubTator, text mining | PubMed |
| Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud. | Cytokine | 2022 | 35687930 | PubTator, text mining | PubMed |
| Genomic characterization of lymphomas in patients with inborn errors of immunity. | Blood Adv | 2022 | 35687490 | PubTator, text mining | PubMed |
| The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. | Front Pharmacol | 2022 | 35685630 | PubTator, text mining | PubMed |
| CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. | Cells | 2022 | 35681499 | PubTator, text mining | PubMed |
| Identification of Potential Biomarkers for Pan-Cancer Diagnosis and Prognosis Through the Integration of Large-Scale Transcriptomic Data. | Front Pharmacol | 2022 | 35677427 | PubTator, text mining | PubMed |
| Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy. | Front Immunol | 2022 | 35677048 | PubTator, text mining | PubMed |
| Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics. | Discov Oncol | 2022 | 35674844 | PubTator, text mining | PubMed |
| Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? | J Hematol Oncol | 2022 | 35672793 | PubTator, text mining | PubMed |
| Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy. | Signal Transduct Target Ther | 2022 | 35665742 | PubTator, text mining | PubMed |
| MCM10 is a Prognostic Biomarker and Correlated With Immune Checkpoints in Ovarian Cancer. | Front Genet | 2022 | 35664337 | PubTator, text mining | PubMed |
| Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways. | Front Immunol | 2022 | 35663987 | PubTator, text mining | PubMed |
| Title: Multi-Omics and Immune Landscape of Proliferative LncRNA Signatures: Implications for Risk Stratification and Immunotherapy in Hepatocellular Carcinoma. | Front Pharmacol | 2022 | 35662721 | PubTator, text mining | PubMed |
| A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment. | BMC Cancer | 2022 | 35659630 | PubTator, text mining | PubMed |
| Characteristics of the cancer stem cell niche and therapeutic strategies. | Stem Cell Res Ther | 2022 | 35659296 | PubTator, text mining | PubMed |
| Inherited TNFSF9 deficiency causes broad Epstein-Barr virus infection with EBV+ smooth muscle tumors. | J Exp Med | 2022 | 35657354 | PubTator, text mining | PubMed |
| Pancancer Analyses Reveal Genomics and Clinical Characteristics of the SETDB1 in Human Tumors. | J Oncol | 2022 | 35656340 | PubTator, text mining | PubMed |
| Comprehensive Analysis of a Ferroptosis Pattern and Associated Prognostic Signature in Acute Myeloid Leukemia. | Front Pharmacol | 2022 | 35656299 | PubTator, text mining | PubMed |
| Targeting Differential Roles of Tumor Necrosis Factor Receptors as a Therapeutic Strategy for Glaucoma. | Front Immunol | 2022 | 35651608 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=69